Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House

Stock Information for Champions Oncology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Champions Oncology Inc.

CORRECTION: Champions Oncology Reports Quarterly Revenue of $14.0 Million
Champions Oncology Reports Record Quarterly Revenue of $14.0 Million
Champions Oncology to Announce First Quarter Financial Results on Monday, September 15, 2025
Champions Oncology Reports Record Annual Revenue of $57 Million
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Wednesday, July 23, 2025
Champions Oncology Announces Appointment of New CEO
Champions Oncology Launches Radiopharmaceutical Services Platform, Expands Isotope License, and Screens More Than 30 PDX Models
Champions Oncology's Data Platform Gains Momentum through a Strategic Collaboration with Turbine

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.